Market Size & Trends
The market for treatments for aorto-iliac occlusive disease (iliac disease) in the United States was valued at USD 716.6 million in 2024 and is expected to expand at a compound annual growth rate (CAGR) of 5.4% between 2025 and 2030. Market expansion is driven by increased government initiatives, rising PAD prevalence, and technological improvements. For example, Philips just began the THOR IDE clinical study in the United States in November 2024 to assess a new hybrid catheter device that combines intravascular lithotripsy and laser atherectomy.
The tool is intended to treat severely calcified lesions that are frequently seen in aorto-iliac illness and PAD. The Cardiovascular Institute of the South in Louisiana performed the first successful patient treatment, highlighting the device's potential to simplify intricate interventions and enhance operative results. Market expansion is fueled by an increase in government initiatives. According to the June 2023 article on Congress.Gov, the Arterial and Venous Comprehensive (ARC) Act was a major step taken by the U.S. government to improve early detection and management of Peripheral Artery Disease (PAD), a major cause of Aorto-Iliac Occlusive Disease. In order to guarantee that Medicare and Medicaid beneficiaries who have been designated as high-risk can obtain PAD screening without having to pay out-of-pocket, this proposal suggests amending the Social Security Act.
Ankle-brachial index (ABI) testing and arterial duplex scans are covered diagnostic techniques that are essential for detecting PAD and determining the severity of the illness in the aorto-iliac area. The ARC Act, which authorizes USD 6 million in funding annually from 2024 to 2028, aims to enhance early diagnosis and prompt intervention, which could lessen the burden of advanced occlusive conditions and increase demand for specific treatment options like revascularization therapies and iliac stenting. This program enables wider access to vital vascular health treatments and encourages preventive care.
The increase in procedure volumes for vascular treatments, including those for aorto-iliac occlusive disease, is largely due to the expansion of office-based laboratories (OBLs) and ambulatory surgery centers (ASCs) throughout the United States. These facilities provide a convenient and affordable substitute for conventional hospital settings, allowing for faster patient turnaround, lower administrative expenses, and more scheduling flexibility for both doctors and patients. In ASCs and OBLs, iliac artery interventions—such as balloon angioplasty, stenting, and atherectomy—are therefore being carried out more frequently, particularly for patients who present with the disease in its early to intermediate stages. These minimally invasive procedures can often be completed on an outpatient basis, making them well-suited to these settings where shorter recovery times and lower procedural risk are prioritized. The shift toward these centers is also supported by favorable reimbursement policies, making them a preferred site of care for providers and payers.
Market Concentration & Characteristics
Due to robust R&D pipelines, ongoing technical improvements, and a dynamic regulatory and reimbursement environment that encourages new therapies, the U.S. market exhibits a high degree of innovation in the treatment of aorto-iliac occlusive disease.
Due to the strategic consolidation, technology acquisition, and portfolio expansion of key competitors, the U.S. market for peripheral arterial disease (PAD) and iliac artery interventions has experienced moderate to high levels of M&A activity. To bolster their peripheral vascular portfolios, big businesses like Abbott, Boston Scientific, Medtronic, and BD (Becton Dickinson) have purchased smaller companies or product lines.
The regulatory environment in the United States has a significant impact on the treatment landscape for AIOD. Although they guarantee patient safety, product quality, and evidence-based treatment, they also provide difficulties with regard to payment uncertainty, compliance expenses, and approval schedules.
The demand for minimally invasive solutions, the development of outpatient care models, and technological innovation are all driving the substantial product and service expansion of the U.S. market for the treatment of aorto-iliac occlusive disease. The United States is now a global leader in complete vascular care thanks to this expansion, which includes novel devices, procedural treatments, diagnostic services, and care delivery methods.
Report Coverage & Deliverables
The PDF report & online dashboard will help you understand
- Competitive benchmarking
- Historical data & forecasts
- Company revenue shares
- Regional opportunities
- Latest trends & dynamics
Device Type Insights
In 2024, the endovascular devices section had the biggest share, accounting for 87.8%. Supporting a variety of methods to restore perfusion in patients with peripheral arterial and aorto-iliac illness, this segment serves as a fundamental component of vascular intervention. As endovascular procedures continue to supplant open surgery in many situations, there is an increasing need for accurate, flexible, and long-lasting equipment. This segment has developed into a broad range that supports customized treatment options across lesion types and complexity, ranging from basic lumen expansion utilizing balloon angioplasty devices to sophisticated anatomical repair with bifurcated aortic stent grafts. An essay assessing artificial intelligence's contribution to the autonomous navigation of guidewires and catheters for endovascular procedures was published in Frontiers in Human Neuroscience in October 2023. The majority of the 14 research studies that were examined in this systematic review used expert demonstration and reinforcement learning approaches with either in-silico models or physical phantoms.
A common first-line strategy or method for preparing arteries prior to stent implantation is balloon angioplasty, which is still a fundamental procedure. Procedural durability has been improved by the development of self-expanding and balloon-expandable stents, each of which offers unique advantages based on the location of the lesion and vascular compliance. The use of covered stent grafts is growing in situations when artery wall integrity is reduced or in high-risk occlusions. Atherectomy systems, albeit more specialized, are essential for altering highly diseased or calcified lesions to improve long-term patency and procedural success rates. Additionally, these devices lower the risk of restenosis and lessen the necessity for adjunctive operations.
End-use Insights
In 2024, the hospitals section had the biggest share, accounting for 49.2%. For the management of complex vascular disorders, hospitals offer extensive infrastructure, cutting-edge technologies, and interdisciplinary competence. Without prompt treatment, AIOD can result in life-threatening consequences such as tissue necrosis, chronic discomfort, and severe limb ischemia. The requirement for highly precise operations and post-procedure care is another factor driving the rising demand for hospital-based treatment. For example, in November 2024, the ROTAPRO system, running at 160,000 RPM, was successfully used by FV Hospital in Vietnam to treat a patient with highly calcified coronary arteries. Due to their access to state-of-the-art technologies, highly qualified medical staff, and interdisciplinary teams that are adept at managing complex vascular conditions, hospitals are uniquely positioned to offer such high-level care and advanced intervention, which lowers risk and recovery time in conditions like AIOD.
Over the course of the forecast period, outpatient facilities are anticipated to expand at the fastest rate. Modern imaging and endovascular equipment are becoming more and more common in ambulatory surgical centers (ASCs) and specialty vascular clinics, enabling them to provide efficient procedures for an expanding patient population. Additionally, outpatient facilities offer greater schedule flexibility and accessibility, which helps to minimize care delays—a critical component in the management of progressive vascular diseases like AIOD.
Procedure Insights
With 61.1% of the market in 2024, the endovascular procedure sector was the largest. Because of their shorter recovery periods and decreased invasiveness, endovascular procedures have emerged as a crucial part of the management of aorto-iliac occlusive disease. These methods are increasingly being used as first-line therapies in less complicated instances and are particularly well-suited for high-risk surgical candidates.
Because of their procedural effectiveness and capacity to restore artery patency with little stress, procedures including balloon angioplasty and primary stenting are frequently used. A case report on LeRiche Syndrome, including aortoiliac and superficial femoral artery occlusion, was published in the Journal of Cardiovascular Medicine and Surgery in December 2024. Significant symptom reduction and restored femoral pulses were the outcomes of the patient's combined aortoiliac stenting and superficial femoral artery angioplasty procedures. This study emphasizes the need for comprehensive vascular evaluation and specialized treatment plans in situations of complicated peripheral artery disease.
In cases of complex bifurcation or calcified lesions, the availability of device-specific techniques such as kissing stents and covered stent grafts has improved results. These choices enable customized treatment of diseases that are architecturally difficult, particularly those involving diffuse iliac involvement or the aortic bifurcation.
Over the course of the projected period, the hybrid procedures segment is anticipated to increase significantly. Using the advantages of both open surgery and endovascular methods, hybrid treatments treat difficult aorto-iliac occlusive disease. In order to treat lesions that are challenging to treat with either technique alone, these procedures usually combine direct surgical exposure of arteries with catheter-based therapies like angioplasty or stenting. In high-risk or anatomically difficult cases, hybrid techniques seek to minimize invasiveness while preserving the longevity of open repair, improving patient outcomes.
Key U.S. Aorto-iliac Occlusive Disease (Iliac Disease) Treatment Company Insights
Some key established players operating in the market include Abbott, Boston Scientific Corporation, Medtronic, W. L. Gore & Associates, Inc., Terumo Corporation, and Cook. These companies are collaborating with regional players to expand their services geographically. iVascular, Limflow, and Vesper Medical are some emerging market participants. Emerging players focus more on collaborating with various research institutions to improve their clinical reach across the healthcare ecosystem.
Key U.S. Aorto-iliac Occlusive Disease (Iliac Disease) Treatment Companies
- BD
- Abbott
- Boston Scientific Corporation
- W. L. Gore & Associates, Inc.
- Medtronic
- Cook
- Terumo Corporation
- Getinge AB
Recent Developments
-
In March 2024, Cook Medical entered into an exclusive distribution agreement with Getinge for the iCast covered stent system in the U.S. This collaboration aims to enhance the device's availability and distribution, which is indicated for the treatment of iliac arterial occlusive disease.
-
In February 2023, Abbott announced the acquisition of Cardiovascular Systems Inc., a medical device company specializing in devices for treating coronary and peripheral artery diseases. This acquisition aimed to enhance Abbott's vascular device portfolio, particularly in treating complex peripheral artery disease cases.
-
In May 2022, iVascular announced the beginning of a trial for its latest product, the advanced covered stent named iCover. This product is designated for treating de novo aortoiliac lesions in individuals experiencing symptomatic arteriopathy of the lower limbs.
U.S. Aorto-iliac Occlusive Disease Treatment Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2025 |
USD 752.5 million |
|
Revenue forecast in 2030 |
USD 978.6 million |
|
Growth rate |
CAGR of 5.4% from 2025 to 2030 |
|
Actual data |
2018-2024 |
|
Forecast period |
2025-2030 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2030 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Segments covered |
Device type, procedure, end-use |
|
Key companies profiled |
BD; Abbott; Boston Scientific Corporation; W. L. Gore & Associates, Inc.; Medtronic; Cook; Terumo Corporation; Getinge AB |
|
Customization scope |
We offer free report customization, equivalent to up to 8 analyst's working days, when you make a purchase. Addition or alteration to country, regional & segment scope. |
|
Pricing and purchase options |
Avail yourself of customized purchase options to meet your exact research needs. Explore purchase options |
U.S. Aorto-iliac Occlusive Disease Treatment Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the subsegments from 2018 to 2030. For this study, MIR has segmented the U.S. aorto-iliac occlusive disease (iliac disease) treatment market report based on device type, procedure, and end-use
-
Device Type Outlook (Revenue, USD Million, 2018 - 2030)
-
Endovascular Devices
-
Balloon Angioplasty Devices
-
Atherectomy Systems
-
Stents
-
Self-Expanding Stents
-
Balloon-Expandable Stents
-
Covered Stent Grafts
-
Bifurcated Aortic Stent Grafts
-
-
-
Surgical Devices
-
-
Procedure Outlook (Revenue, USD Million, 2018 - 2030)
-
Endovascular Procedures
-
Balloon Angioplasty
-
Primary Stenting
-
Kissing Stents
-
Covered Stent Grafts
-
Endovascular Aortic Repair (EVAR)
-
-
Hybrid Procedures
-
Open Surgical Procedures
-
-
End-use Outlook (Revenue, USD Million, 2018-2030)
-
Hospitals
-
Outpatient Facilities
-
Others
-
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy